Related Experiment Videos
Lumenal route for intestinal radioprotection
J P Delaney1, M E Bonsack, I Felemovicius
1Department of Surgery, University of Minnesota Medical School, Minneapolis.
American Journal of Surgery
|November 1, 1993
Summary
Intralumenal agents offer a promising strategy for intestinal radioprotection, minimizing systemic effects. Lumenal Lazaroid demonstrated significant protection against radiation injury in the small bowel.
Area of Science:
- Radiation oncology
- Gastroenterology
- Pharmacology
Background:
- Intestinal radiation injury limits abdominal and pelvic radiation therapy efficacy.
- Systemic radioprotective agents often cause toxicity and may harm tumors.
- Intralumenal administration allows targeted mucosal protection with reduced systemic exposure.
Purpose of the Study:
- To review studies on intralumenal agents for intestinal radioprotection.
- To evaluate the efficacy of various intralumenal agents in a rat small bowel model.
Main Methods:
- Irradiation of exteriorized rat small bowel segments containing intralumenal drugs.
- Quantification of surviving crypts 5 days post-irradiation to assess injury.
- Comparison of injury levels between treated and control segments.
Main Results:
- Modest protection observed with lumenal alkalinization, bile salt neutralization, and pancreatic enzyme neutralization.
- Nonsteroidal anti-inflammatory agents, methylprednisolone, and antioxidants provided similar levels of protection.
- Significant radioprotection was achieved with lumenal Lazaroid administration.
Conclusions:
- Intralumenal agents can effectively protect the intestine from radiation injury.
- Lazaroid is a particularly effective intralumenal agent for intestinal radioprotection.
- This approach offers a targeted strategy to mitigate radiation-induced gastrointestinal toxicity.